Artwork
iconShare
 
Manage episode 509529270 series 2864794
Content provided by Biotech Connection Los Angeles, Gabriella Rubert, Daniel Arce, Katherine Merkling, Serena Gao, Bryan Jimenez, Danielle Luu, and Stephanie Wu. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Biotech Connection Los Angeles, Gabriella Rubert, Daniel Arce, Katherine Merkling, Serena Gao, Bryan Jimenez, Danielle Luu, and Stephanie Wu or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Serial entrepreneur Michael Heltzen, CEO of Exozymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, Exozymes isolates enzymatic pathways to work as pure chemistry—achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses Exozymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting.

Make sure to check out eXoZymes' website: https://exozymes.com/

Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!

To learn more about BCLA’s events and consulting visit our website.

Follow BCLA on LinkedIn

  continue reading

35 episodes